Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Unconventional wisdom: A controversial income pick
Rigid definitions of income and growth shares may be holding investors back.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
Why ASX miners will handily beat banks in the long-term
After a stellar run for banks, investors are wondering whether they can continue their outperformance or if a rotation into miners is imminent. There’s a good case that a switch is coming, and it may last decades, not just years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,780.30 | 4.80 | -0.05% |
| CAC 40 | 7,991.52 | 16.10 | -0.20% |
| DAX 40 | 21,874.69 | 27.73 | -0.13% |
| Dow JONES (US) | 44,431.67 | 315.96 | -0.71% |
| FTSE 100 | 8,706.55 | 20.73 | -0.24% |
| HKSE | 21,133.54 | 241.92 | 1.16% |
| NASDAQ | 19,539.04 | 252.95 | -1.28% |
| Nikkei 225 | 38,787.02 | 279.51 | -0.72% |
| NZX 50 Index | 12,902.19 | 57.60 | 0.45% |
| S&P 500 | 6,036.30 | 47.27 | -0.78% |
| S&P/ASX 200 | 8,511.40 | 9.30 | -0.11% |
| SSE Composite Index | 3,303.67 | 33.01 | 1.01% |